Please use this identifier to cite or link to this item:
|Title:||Terlipressin: current and emerging indications in chronic liver disease||Austin Authors:||Papaluca, Timothy ;Gow, Paul J||Affiliation:||Austin Health, Heidelberg, Victoria, Australia||Issue Date:||Mar-2018||metadata.dc.date:||2017-10-05||Publication information:||Journal of Gastroenterology and Hepatology 2018; 33(3): 591-598||Abstract:||Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding and disruptions in sodium homeostasis. Novel methods of infusion based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/16905||DOI:||10.1111/jgh.14009||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/28981166||Type:||Journal Article||Subjects:||Hepatorenal syndrome
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 25, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.